Calyxt, Inc., a plant-based synthetic biology company, announced the placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock.
February 17, 2022
· 5 min read